$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
卡博替尼——口服酪氨酸激酶抑制剂治疗甲状腺髓样癌的活性
2025-10-19 11:44:20
Check Details
肾癌靶向药物多吉美和舒尼替尼
2025-10-19 11:44:20
Check Details
乐伐替尼与依维莫司合并用药治疗晚期肾癌
2025-10-19 11:44:20
Check Details
卡博替尼±厄洛替尼治疗非小细胞肺癌研究
2025-10-19 11:44:20
Check Details
卡博替尼治疗去势抵抗前列腺癌和骨转移:剂量范围研究
2025-10-19 11:44:20
Check Details
卡博替尼治疗肾癌优于舒尼替尼
2025-10-19 11:44:20
Check Details
卡博替尼用于接受过化疗的转移性去势抵抗前列腺癌:II期非随机扩展研究
2025-10-19 11:44:20
Check Details
舒尼替尼用于肾癌患者术后辅助治疗的有效性
2025-10-19 11:44:20
Check Details
卡博替尼治疗转移性去势抵抗前列腺癌:III期COMET-1研究
2025-10-19 11:44:20
Check Details
厄洛替尼vs卡博替尼vs卡博替尼加厄洛替尼作为EGFR野生型肺癌二线或三线治疗
2025-10-19 11:44:20
Check Details
乐伐替尼联合依维莫司延长肾癌患者生存期
2025-10-19 11:44:20
Check Details
舒尼替尼治疗晚期肾细胞癌
2025-10-19 11:44:20
Check Details
1
2
...
8176
8177
8178
8179
8180
8181
8182
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Etrasimod for Ulcerative Colitis: 2mg Once Daily, Onset Timeline, and Safety Monitoring
2
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
3
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
4
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
5
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
6
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
7
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
8
Bedaquiline for Drug-Resistant TB: 24-Week Regimen, Combination Duration, and When to Stop or Extend
9
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
10
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
11
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
12
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks